Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Blood Advances|November 19, 2024
Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLLJacob D Soumerai, Jacqueline Barrientos, Inhye Ahn, et al.
British Journal of Haematology|March 19, 2024
Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomasJacob D Soumerai, Catherine S Diefenbach, Deepa Jagadeesh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2009
Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180Steven P Treon, Leukothea Ioakimidis, Jacob D Soumerai, et al.
American Journal of Hematology|October 23, 2024
Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosisLeon D Kaulen, Philipp Karschnia, Sofia Doubrovinskaia, et al.
Blood Advances|March 26, 2026
A phase I/II Study of Duvelisib plus Venetoclax in Patients with Relapsed/Refractory CLL/SLL or Richter TransformationJennifer L Crombie, Christine E Ryan, Yue Ren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Lenalidomide and rituximab in Waldenstrom's macroglobulinemiaSteven P Treon, Jacob D Soumerai, Andrew R Branagan, et al.
Blood|January 25, 2008
CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemiaAllen W Ho, Evdoxia Hatjiharissi, Bryan T Ciccarelli, et al.
Leukemia & Lymphoma|February 21, 2024
Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOPRonald Nemec, Marielle Scherrer-Crosbie, Jeremy S Abramson, et al.
Blood|February 28, 2019
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cellsPhilipp Karschnia, Justin T Jordan, Deborah A Forst, et al.
Journal of Hematology & Oncology|January 14, 2026
Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphomaLeon D Kaulen, Philipp Karschnia, Sofia Doubrovinskaia, et al.
Pageof 5